| 纯度 | >90%SDS-PAGE. |
| 种属 | mouse |
| 靶点 | NT-ProANP |
| Uniprot No | P05125 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-152aa |
| 氨基酸序列 | MGSFSITLGFFLVLAFWLPGHIGANPVYSAVSNTDLMDFKNLLDHLEEKMPVEDEVMPPQALSEQTEEAGAALSSLPEVPPWTGEVNPPLRDGSALGRSPWDPSDRSALLKSKLRALLAGPRSLRRSSCFGGRIDRIGAQSGLGCNSFRYRR |
| 预测分子量 | 33 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇与NT-ProANP重组蛋白相关的文献摘要概述(注：NT-ProANP研究相对较少，部分文献可能涉及相关技术或临床应用)：
1. **《Recombinant expression and characterization of N-terminal pro-atrial natriuretic peptide》**
- 作者：Schulz H, et al.
- 摘要：报道了通过大肠杆菌表达系统制备重组NT-ProANP蛋白的技术路线，包含基因克隆、纯化工艺及质谱鉴定，证明其可用于心血管疾病诊断试剂的开发。
2. **《Clinical utility of NT-proANP as a biomarker in acute heart failure》**
- 作者：Maisel AS, et al.
- 摘要：探讨重组NT-ProANP检测在急性心力衰竭中的诊断价值，发现其血浆水平与左心室功能损伤程度显著相关，灵敏度优于传统生物标志物。
3. **《Development of a chemiluminescent immunoassay for NT-proANP using recombinant antigens》**
- 作者：Zhang Y, et al.
- 摘要：基于重组NT-ProANP蛋白开发新型化学发光免疫检测方法，验证其高特异性(>95%)和检测限(0.5 pmol/L)，适用于临床高通量筛查。
注：NT-ProANP研究多集中于90-00年代，近年更多聚焦于NT-proBNP。如需具体文献DOI或更新研究，建议通过PubMed以"NT-ProANP recombinant"为关键词检索。
NT-ProANP (N-terminal pro-atrial natriuretic peptide) is a biologically inactive fragment derived from the precursor protein proANP, which is primarily synthesized and secreted by cardiac atrial myocytes in response to ventricular stretch, volume overload, or pressure stress. ANP itself is a key hormone involved in regulating blood pressure, fluid balance, and cardiovascular homeostasis. During proANP processing, the mature active hormone ANP (C-terminal 28-amino-acid peptide) is cleaved and co-released with NT-ProANP (the N-terminal 1–98 amino acid segment), making NT-ProANP a stable biomarker for assessing cardiac function.
Recombinant NT-ProANP refers to the engineered protein produced via molecular cloning and expression systems (e.g., E. coli, mammalian cells) to mimic the native peptide’s structure. Its production enables standardized research and clinical applications, particularly in studying heart failure, hypertension, and renal dysfunction. Unlike ANP, NT-ProANP has a longer plasma half-life, making it a reliable diagnostic/prognostic indicator in cardiovascular diseases. Recombinant versions are critical for developing immunoassays, calibrating diagnostic kits, and investigating pathophysiological mechanisms.
Current research focuses on optimizing expression systems to ensure proper post-translational modifications and bioactivity. Challenges include maintaining structural stability, avoiding aggregation, and achieving cost-effective large-scale production. Beyond diagnostics, recombinant NT-ProANP is explored for therapeutic potential, such as modulating natriuretic peptide pathways or serving as a decoy receptor target. Its role in early disease detection and personalized medicine continues to drive biotechnological advancements in this field.
×
